<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045548</url>
  </required_header>
  <id_info>
    <org_study_id>dinoprostone IUD</org_study_id>
    <nct_id>NCT04045548</nct_id>
  </id_info>
  <brief_title>Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery</brief_title>
  <official_title>Benefits of Vaginal Dinoprostone Administration Prior to Levonorgestrel-releasing Intrauterine System Insertion in Women Delivered Only by Elective Cesarean Section: a Randomized Double-blind Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether vaginal dinoprostone administered before the levonorgestrel-releasing
      intrauterine system(IUs) insertion reduces failed insertions, insertion-related
      complications, and pain in Women With no Previous Vaginal Delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-acting reversible contraception methods are highly effective methods for reduction of
      the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that
      provides reliable, effective and long term contraception for many women. However, the
      insertion procedure can be associated with a troublesome degree of pain that prevent some
      women from choosing its use. Different interventions have been described to decrease pain
      perception during intrauterine device insertion with no agreement on an effective one.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Actual">January 5, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in pain scores during intrauterine device insertion</measure>
    <time_frame>10 minutes</time_frame>
    <description>The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Intrauterine Device</condition>
  <arm_group>
    <arm_group_label>dinoprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.</description>
    <arm_group_label>dinoprostone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant women

          -  Women that did not receive any analgesics or Dinoprostone in the 24 hours prior to
             insertion

          -  Women who delivered only by cesarean section

        Exclusion Criteria:

          -  Women with any uterine abnormalities as congenital anomalies, endometrial lesions,
             adenomyosis, fibroids.

          -  Those with a Category 3 or 4 conditions for intrauterine device insertion according to
             the WHO Medical Eligibility Criteria for contraceptive use

          -  Allergy to dinoprostone.

          -  Women refuse to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine Cairo university</name>
      <address>
        <city>Cairo</city>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

